Craig Thomson

Craig is recognised for providing pragmatic, commercially focused advice to clients in the biotechnological, pharmaceutical, chemical and MedTech sectors. As well as patent drafting and prosecution, Craig advises on the development of company-wide IP strategies, funding/acquisition due-diligence, and aggressive/defensive strategies in relation to third-party IP.

Having worked closely with multi-national corporations, Craig understands the challenges associated with efficiently prosecuting large multi-national patent portfolios, whilst keeping them relevant to the business. He values this experience as it helps him to provide expert guidance to SMEs as they grow or prepare for acquisition. Whilst part of Craig’s focus is ensuring that technical aspects of each invention is accurately captured in a patent, he understands that the value of IP can only be fully realised after understanding the commercial goals of a business, and how IP can best be exploited to help underpin those goals. It is therefore important for him to understand more generally his client’s business; enabling him to provide them with a more broad-ranging, effective and valuable set of solutions. Industry sectors for which Craig has considerable knowledge of include those concerned with the microbiome, food, formulations, anti-infectives, diagnostics and MedTech.

Craig has a proven track record of providing successful outcomes for clients, both in a wide-range of legal proceedings (including opposition, entitlement, and USPTO interviews) and in successful IP-license/assignment deals involving patents that he both drafted and prosecuted to grant. He has co-written an amicus curiae (filed with the US Supreme Court for Sequenom v Ariosa), and has assisted many clients to successfully obtain investment, including listing on AIM.